Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05806996 · ClinicalTrials.gov registry record · Phase 2
A Study of Magnesium and Bladder Spasms Following Ambulatory Urologic Procedures
A Phase 2 study of Bladder Spasms, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT05806996: Recruiting Phase 2 study of Bladder Spasms, sponsored by Mayo Clinic.
NCT05806996 is a Phase 2 study of Bladder Spasms that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 120 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (10% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05806996, a Phase 2 study of Bladder Spasms, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
This research is being done to find out whether intravenous magnesium is effective in the treatment of bladder spasms after urologic surgery.
Primary Outcome
Number of subjects to experience bladder spasms
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Magnesium
Study Locations (1)
Minnesota
- Mayo Clinic in Minnesota - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2023-07-31 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
What NCT05806996 shows while recruiting
NCT05806996 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (10% lower).
The record links to 1 condition, with Bladder Spasms appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05806996 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT05806996 about?
NCT05806996 is a clinical study titled "A Study of Magnesium and Bladder Spasms Following Ambulatory Urologic Procedures". This research is being done to find out whether intravenous magnesium is effective in the treatment of bladder spasms after urologic surgery.
What is the current status of trial NCT05806996?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2023-07-31. Estimated completion is 2026-12-31.
What conditions does trial NCT05806996 study?
This clinical trial studies the following conditions: Bladder Spasms.
What interventions are being tested in trial NCT05806996?
The interventions under investigation include: Placebo (DRUG), Magnesium (DRUG).
Who is sponsoring clinical trial NCT05806996?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05806996 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05806996's enrollment target sits among peer trials
120 569th of 2000 higher than 1,384 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI